Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Chronic GVHD
NCT04692376Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mesenchymal stem cells in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04692376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692376.